The utility of prostate-specific antigen velocity thresholds in clinical practice: A population-based analysis

BJU International

Volumn 101, Issue 12, 2008, Pages 1507-1512

  Connolly, David ^a,b   Black, Amanda ^b   Murray, Liam J ^b   Nambirajan, Thiagarajan ^a   Keane, Patrick F ^a   Gavin, Anna ^b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cancer; Diagnosis; Initial PSA; Population; Prostate; Velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER INVASION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HOSPITAL DISCHARGE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

AGED; COHORT STUDIES; HUMANS; IRELAND; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 43949129786     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07470.x     Document Type: Article

References (29)

1. American Cancer Society. Cancer Facts and Figures, 2006. Atlanta : American Cancer Society, 2006. Available at: http://www.cancer.org/downloads/ STT/CAFF2006PWSecured.pdf. Accessed 21 June 2007
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005 16 : 481 8
3. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005 23 : 8146 51
4. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 94 : 981 90
5. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 95 : 868 78
6. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004 350 : 2239 46
7. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992 267 : 2215 20
8. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994 152 : 1163 7
9. Mettlin C, Murphy GP, Lee F et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994 152 : 1737 40
10. Berger AP, Deibl M, Steiner H et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 2005 64 : 240 5
11. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 351 : 125 35
12. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005 294 : 440 7
13. Perrin P. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence. Eur Urol 2006 49 : 418 9
14. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002 59 : 889 93
15. Loeb S, Roehl KA, Catalona WJ, Nadler RB. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007 177 : 899 902
16. Moul JW, Sun L, Hotaling JM et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007 177 : 499 503
17. Raaijmakers R, Wildhagen MF, Ito K et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004 63 : 316 20
18. Roobol MJ, Kranse R, de Koning HJ, Schroder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (Rotterdam). Urology 2004 63 : 309 13
19. Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006 49 : 460 5 discussion A, McCarron P, Middleton RJ et al. Evidence of prostate cancer screening in a UK region. BJU Int 2004 93 : 730 4
20. Connolly D, Black A, Napolitano G, Murray LJ, Gavin A, Keane PF. Methods of calculating prostate specific antigen velocity. Eur Urol 2007 52 : 1044 50
21. Connolly D. Long Term Follow-Up of Men with Elevated Prostate Specific Antigen Levels: A Population Based Study. MD Thesis. Belfast : Queen's University Belfast, 2007
22. Carter HB, Pearson JD, Waclawiw Z et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995 45 : 591 6
23. Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989 141 : 1076 83
24. Soletormos G, Semjonow A, Sibley PE et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005 51 : 1342 51
25. Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005 294 : 66 70
26. Carter HB, Ferrucci L, Kettermann A et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006 98 : 1521 7
27. Freedland SJ, Dorey F, Aronson WJ. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001 57 : 476 80
28. Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol 1997 158 : 1876 8
29. Pinsky PF, Andriole G, Crawford ED et al. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer 2007 109 : 1689 95